Technical Analysis for EYES - Second Sight Medical Products, Inc.

Grade Last Price % Change Price Change
grade F 0.71 0.00% 0.00
EYES closed unchanged on Friday, May 24, 2019, on 1.66 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical EYES trend table...

Date Alert Name Type % Chg
Jack-in-the-Box Bearish Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%

Older signals for EYES ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Second Sight Medical Products, Inc. was founded in 1998 with a mission to restore vision to the blind. Today, Second Sight’s Argus II retinal prosthesis provides functional vision to patients blinded by outer retinal degenerations such as retinitis pigmentosa. The company’s innovative technology is the only retinal prosthesis approved by the United States FDA and the first device to receive a CE mark in Europe. The company’s transformative prosthetic device allows blind individuals to gain greater independence in their daily lives. Second Sight believes that its award winning technology will serve as a platform to treat nearly all forms of blindness and could be extended to other neurostimulation applications beyond vision restoration. The Argus II system is currently available in the US and Europe and the company is actively pursuing additional geographic markets. With next generation products under development, the company plans to continue developing, manufacturing and marketing its innovative visual prostethics around the world. Second Sight’s US Headquarters are in Sylmar, California. European Headquarters are in Lausanne, Switzerland.
Medicine Biotechnology Emerging Technologies Medical Devices FDA Vision Blindness Retinitis Pigmentosa Biomedical Engineering Neuroprosthetics Neurostimulation
Is EYES a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.15
52 Week Low 0.635
Average Volume 304,492
200-Day Moving Average 1.1581
50-Day Moving Average 0.9043
20-Day Moving Average 0.9178
10-Day Moving Average 0.8682
Average True Range 0.0699
ADX 24.67
+DI 16.9769
-DI 26.7437
Chandelier Exit (Long, 3 ATRs ) 0.8393
Chandelier Exit (Short, 3 ATRs ) 0.9097
Upper Bollinger Band 1.0946
Lower Bollinger Band 0.741
Percent B (%b) -0.09
BandWidth 38.526912
MACD Line -0.04
MACD Signal Line -0.0103
MACD Histogram -0.0297
Fundamentals Value
Market Cap 40.32 Million
Num Shares 56.8 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -1.00
Price-to-Sales 12.04
Price-to-Book 3.29
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.85
Resistance 3 (R3) 0.86 0.82 0.82
Resistance 2 (R2) 0.82 0.79 0.82 0.81
Resistance 1 (R1) 0.77 0.77 0.75 0.76 0.81
Pivot Point 0.73 0.73 0.73 0.73 0.73
Support 1 (S1) 0.68 0.70 0.66 0.67 0.61
Support 2 (S2) 0.64 0.68 0.64 0.61
Support 3 (S3) 0.59 0.64 0.60
Support 4 (S4) 0.58